DE2530246A1 - L-aminosaeuregemische fuer parenterale oder orale anwendung - Google Patents
L-aminosaeuregemische fuer parenterale oder orale anwendungInfo
- Publication number
- DE2530246A1 DE2530246A1 DE19752530246 DE2530246A DE2530246A1 DE 2530246 A1 DE2530246 A1 DE 2530246A1 DE 19752530246 DE19752530246 DE 19752530246 DE 2530246 A DE2530246 A DE 2530246A DE 2530246 A1 DE2530246 A1 DE 2530246A1
- Authority
- DE
- Germany
- Prior art keywords
- amino acid
- acid mixtures
- methionine
- parenteral
- phenylalanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 32
- 150000008575 L-amino acids Chemical class 0.000 claims description 28
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 20
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 16
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 16
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 14
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 14
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 14
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 13
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 13
- 229930195722 L-methionine Natural products 0.000 claims description 13
- 229960004452 methionine Drugs 0.000 claims description 13
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 12
- 229960005190 phenylalanine Drugs 0.000 claims description 10
- 239000004473 Threonine Substances 0.000 claims description 8
- 229960002898 threonine Drugs 0.000 claims description 8
- 229960004295 valine Drugs 0.000 claims description 8
- 235000019766 L-Lysine Nutrition 0.000 claims description 7
- 239000004395 L-leucine Substances 0.000 claims description 7
- 235000019454 L-leucine Nutrition 0.000 claims description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 229960003136 leucine Drugs 0.000 claims description 7
- 229960004799 tryptophan Drugs 0.000 claims description 7
- 229960002885 histidine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-AKGZTFGVSA-N (2s)-2-amino-3-methylpentanoic acid Chemical compound CCC(C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-AKGZTFGVSA-N 0.000 claims description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 5
- 229960004441 tyrosine Drugs 0.000 claims description 4
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 3
- 239000004158 L-cystine Substances 0.000 claims description 3
- 235000019393 L-cystine Nutrition 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 229960003067 cystine Drugs 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000003978 infusion fluid Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 229960003646 lysine Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 229930182844 L-isoleucine Natural products 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 206010010075 Coma hepatic Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 201000001059 hepatic coma Diseases 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- -1 hematocrit Proteins 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000020905 low-protein-diet Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752530246 DE2530246A1 (de) | 1975-07-07 | 1975-07-07 | L-aminosaeuregemische fuer parenterale oder orale anwendung |
| FR7620325A FR2316933A1 (fr) | 1975-07-07 | 1976-07-02 | Melanges de l-aminoacides et leur utilisation therapeutique pour le traitement d'insuffisances hepatiques et renales. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752530246 DE2530246A1 (de) | 1975-07-07 | 1975-07-07 | L-aminosaeuregemische fuer parenterale oder orale anwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2530246A1 true DE2530246A1 (de) | 1977-01-13 |
| DE2530246C2 DE2530246C2 (enExample) | 1989-08-03 |
Family
ID=5950870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752530246 Granted DE2530246A1 (de) | 1975-07-07 | 1975-07-07 | L-aminosaeuregemische fuer parenterale oder orale anwendung |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE2530246A1 (enExample) |
| FR (1) | FR2316933A1 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2531204A1 (de) * | 1975-07-12 | 1977-01-13 | Fresenius Chem Pharm Ind | L-aminosaeuregemische fuer parenterale oder orale anwendung |
| DE2935709A1 (de) * | 1978-09-04 | 1980-03-13 | Otsuka Pharma Co Ltd | Aminosaeureloesungen und deren verwendung |
| JPS58126767A (ja) * | 1982-01-22 | 1983-07-28 | Ajinomoto Co Inc | 肝臓病患者用栄養組成物 |
| JPS5916817A (ja) * | 1982-07-16 | 1984-01-28 | Eisai Co Ltd | アミノ酸輸液 |
| US5646187A (en) * | 1992-05-20 | 1997-07-08 | Ab Erik Vinnars | Use of alpha-ketoglutarate |
| WO1998026774A1 (en) * | 1996-12-16 | 1998-06-25 | Professional Dietetics S.R.L. | Compositions based on aminoacids |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5536457A (en) * | 1978-09-08 | 1980-03-14 | Ajinomoto Co Inc | Amino acid infusion |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1923167A1 (de) * | 1968-05-09 | 1969-11-20 | Astra Ab | Aminosaeureloesung zur intravenoesen Stickstoffzufuhr bei uraemischen Bedingungen und Verfahren zu deren Herstellung |
| DE1667887B1 (de) * | 1968-02-09 | 1971-10-07 | Knauff Hans Georg Prof Dr | Aminosaeureloesungen zur parenteralen Infusion |
| DE2310791A1 (de) * | 1972-03-06 | 1973-09-13 | Howard Alan Norman | Diaetmischungen zur behandlung des uebergewichtes bei menschen |
| DE2335215A1 (de) * | 1972-07-13 | 1974-01-31 | Mackenzie Walser | Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung |
| DE2335216A1 (de) * | 1973-04-30 | 1974-11-21 | Mackenzie Walser | Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3832465A (en) * | 1971-12-09 | 1974-08-27 | H Ghadimi | Injectable amino acid composition commensurate to the anabolic need of the body and method of using same |
| FR2215212B1 (enExample) * | 1973-01-18 | 1976-03-05 | Seperic Ch |
-
1975
- 1975-07-07 DE DE19752530246 patent/DE2530246A1/de active Granted
-
1976
- 1976-07-02 FR FR7620325A patent/FR2316933A1/fr active Granted
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1667887B1 (de) * | 1968-02-09 | 1971-10-07 | Knauff Hans Georg Prof Dr | Aminosaeureloesungen zur parenteralen Infusion |
| DE1923167A1 (de) * | 1968-05-09 | 1969-11-20 | Astra Ab | Aminosaeureloesung zur intravenoesen Stickstoffzufuhr bei uraemischen Bedingungen und Verfahren zu deren Herstellung |
| DE2310791A1 (de) * | 1972-03-06 | 1973-09-13 | Howard Alan Norman | Diaetmischungen zur behandlung des uebergewichtes bei menschen |
| DE2335215A1 (de) * | 1972-07-13 | 1974-01-31 | Mackenzie Walser | Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung |
| DE2335216A1 (de) * | 1973-04-30 | 1974-11-21 | Mackenzie Walser | Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung |
Non-Patent Citations (4)
| Title |
|---|
| DE-B.: Hagers Handbuch der Pharmazeutischen Praxis, Bd.7, 4.Ausg., Springer, Berlin, 1971, S.401-405 * |
| HELWIG B.: Moderne Arzneimittel, Stuttgart, 1972, S.1167-1176 * |
| SCHLOERB P.R.: Am. J. Med. Sci. 252, 1966, S.650-659 * |
| US-Z.: P. Richards et al., The Lancet, 17.07.1971,S.128-134 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2531204A1 (de) * | 1975-07-12 | 1977-01-13 | Fresenius Chem Pharm Ind | L-aminosaeuregemische fuer parenterale oder orale anwendung |
| DE2935709A1 (de) * | 1978-09-04 | 1980-03-13 | Otsuka Pharma Co Ltd | Aminosaeureloesungen und deren verwendung |
| JPS58126767A (ja) * | 1982-01-22 | 1983-07-28 | Ajinomoto Co Inc | 肝臓病患者用栄養組成物 |
| JPS5916817A (ja) * | 1982-07-16 | 1984-01-28 | Eisai Co Ltd | アミノ酸輸液 |
| US5646187A (en) * | 1992-05-20 | 1997-07-08 | Ab Erik Vinnars | Use of alpha-ketoglutarate |
| WO1998026774A1 (en) * | 1996-12-16 | 1998-06-25 | Professional Dietetics S.R.L. | Compositions based on aminoacids |
| US6218420B1 (en) * | 1996-12-16 | 2001-04-17 | Professional Dietetics S.R.L. | Compositions based on aminoacids |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2530246C2 (enExample) | 1989-08-03 |
| FR2316933B1 (enExample) | 1979-06-29 |
| FR2316933A1 (fr) | 1977-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68905387T2 (de) | Aminosäure-Nahrungsmittelzusammensetzungen. | |
| DE69501306T2 (de) | Diätetische Zusammensetzung für Jugendliche | |
| DE2260189C2 (de) | Injizierbare Aminosäurepräparate | |
| DE19521753B4 (de) | Monomere Insulinanalogonformulierungen | |
| DE3026368C2 (enExample) | ||
| CH646874A5 (de) | Naehrloesung. | |
| FLINK et al. | Evidences for clinical magnesium deficiency | |
| DE69006395T2 (de) | Nährstoff-Zusammensetzungen für die Ergänzung an Aminosäuren bei Säugetieren. | |
| DE3302008A1 (de) | Elementare diaet | |
| DE69127087T2 (de) | Wachstumsfaktor und glutamin enthaltendes produkt und verwendung des wachstumsfaktors zur behandlung der darmschleimhaut | |
| DE2936236A1 (de) | Aminosaeureloesung fuer die intravenoese ernaehrung | |
| CH642541A5 (de) | Essentielle aminosaeuren enthaltende loesung zur verabreichung an krebspatienten. | |
| DE69530570T2 (de) | Verfahren zur behandlung von stoehrungen des menschlichen oder tierischen koerpers durch verabreichung von aminosaeuren | |
| DE2921331A1 (de) | Pharmazeutisches mittel und dessen verwendung bei einer vollstaendig parenteralen ernaehrung | |
| DE69331465T2 (de) | Intravenöse lösung, die den protein - und wasserverlust im körper reduziert | |
| DE2530246A1 (de) | L-aminosaeuregemische fuer parenterale oder orale anwendung | |
| DE69220821T2 (de) | Verfahren zur Sicherstellung eines angemessenen intrazellulären Glutathionspiegels im Gewebe | |
| Singer | Dietary protein-induced changes in excretory function: a general animal design feature | |
| EP0399341B1 (de) | Wässrige Zusammensetzung für die parenterale Ernährung | |
| DE60129032T2 (de) | Creatinester-pronutrient-verbindungen und formulierungen | |
| Corman et al. | Effect of feeding on glomerular filtration rate and proteinuria in conscious aging rats | |
| EP0769295B1 (en) | Use of valine for the manufacture of a medicament for liver regeneration | |
| DE69430416T2 (de) | Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen | |
| Kohaut et al. | Reduced renal acid excretion in malnutrition: a result of phosphate depletion | |
| DE2531299C2 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8125 | Change of the main classification |
Ipc: A61K 31/195 |
|
| 8126 | Change of the secondary classification |
Ipc: A61K 31/40 |
|
| 8127 | New person/name/address of the applicant |
Owner name: FRESENIUS AG, 6380 BAD HOMBURG, DE |
|
| D2 | Grant after examination | ||
| 8363 | Opposition against the patent |